Angiogenesis Enhances Factor IX Delivery and Persistence from Retrievable Human Bioengineered Muscle Implants
Open Access
- 30 September 2006
- journal article
- Published by Elsevier BV in Molecular Therapy
- Vol. 14 (3), 442-451
- https://doi.org/10.1016/j.ymthe.2006.03.019
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Preclinical and clinical gene therapy for haemophiliaHaemophilia, 2004
- Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1Blood, 2004
- LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1Science, 2003
- Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectorsBlood, 2003
- Bone marrow stromal cells as a genetic platformfor systemic delivery of therapeutic proteinsin vivo: human factorIX modelThe Journal of Gene Medicine, 2002
- Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivoBlood, 2002
- Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesisHaemophilia, 2001
- Tissue-Engineered Human Bioartificial Muscles Expressing a Foreign Recombinant Protein for Gene TherapyHuman Gene Therapy, 1999
- Tissue-Engineered Skeletal Muscle Organoids for Reversible Gene TherapyHuman Gene Therapy, 1996
- Efficient selection for high-expression transfectants with a novel eukaryotic vectorGene, 1991